Constipation is one of the most commonly reported side effects of semaglutide (Ozempic, Wegovy). Clinical trials found it in up to 24% of people taking the 2.4 mg weekly dose used for weight management, according to the Wegovy FDA prescribing information. It tends to be manageable and often improves as your body adjusts to the medication.
Why Does Semaglutide Cause Constipation?
Semaglutide works by activating GLP-1 receptors throughout the body — including in the gut. According to gastroenterologist Michael Camilleri, writing in the New England Journal of Medicine (2021), GLP-1 receptor agonists slow gastric emptying and reduce the speed at which food moves through the intestines. This slower transit means the large intestine has more time to absorb water from stool, making it harder and more difficult to pass.
Several factors compound this effect:
- Reduced food intake: Eating less means less bulk moving through the colon, which weakens the natural signals that trigger bowel movements.
- Lower fluid intake: Nausea and appetite suppression can cause some people to drink less water than usual.
- Dose escalation: GI side effects, including constipation, are more pronounced after each dose increase.
When Does Constipation Peak on Semaglutide?
Constipation does not stay constant throughout treatment. It typically tracks with dose increases and often improves between escalations. The table below reflects the standard Wegovy dose-escalation schedule and when constipation symptoms are most commonly reported, based on the STEP 1 trial (Wilding et al., NEJM, 2021).
| Weeks | Weekly Dose | Typical Constipation Pattern |
|---|---|---|
| 1–4 | 0.25 mg | Mild; most people experience little disruption at the starter dose |
| 5–8 | 0.5 mg | Symptoms may increase after the first dose increase |
| 9–12 | 1.0 mg | Another potential spike in constipation; gut adapting |
| 13–16 | 1.7 mg | Often the most disruptive escalation step for GI side effects |
| 17 onward | 2.4 mg (maintenance) | Constipation frequently improves once at a stable dose for several weeks |
Most important point: Constipation on semaglutide is rarely permanent. The Wegovy prescribing information reports that GI adverse events were most common during dose escalation and typically declined over time at the maintenance dose. If you go more than five days without a bowel movement, or experience bloating with severe abdominal pain, contact your prescriber promptly.
What Relief Strategies Actually Help?
The following approaches are supported by NIH guidance on constipation management and are consistent with advice commonly given alongside GLP-1 therapy:
- Increase water intake deliberately: The NIH recommends at least 8 cups (64 oz) of fluid per day for adults with constipation. Because semaglutide suppresses thirst cues, setting a timer or using a marked water bottle helps.
- Add soluble fiber gradually: Foods like oats, beans, apples, and psyllium husk attract water into the stool, making it softer. Increase fiber slowly — too much too fast can worsen bloating on an already slow-moving gut.
- Move your body: Even a 20–30 minute walk after meals stimulates intestinal contractions. Physical activity is a first-line recommendation in NIH constipation guidelines.
- Try a stool softener: Over-the-counter docusate sodium (e.g., Colace) draws water into stool and is generally considered safe alongside semaglutide. Ask your pharmacist or prescriber before starting.
- Consider osmotic laxatives: Polyethylene glycol (MiraLAX) works by pulling water into the colon and is recommended by NIH for short-term constipation relief. It does not cause dependency at typical doses.
- Don't ignore the urge: Delaying bowel movements allows more water to be absorbed from stool. Responding promptly to the urge is a basic but often overlooked step.
Are There Foods or Habits That Make It Worse?
Certain patterns that are common among people on semaglutide can unintentionally worsen constipation:
- High-protein, low-fiber eating: Many people naturally shift toward protein-dense foods to preserve muscle while losing weight. Without adequate vegetables, fruit, and whole grains, fiber intake drops sharply.
- Skipping meals: Very low food volume means minimal colonic stimulation.
- Excess dairy or red meat: These are low in fiber and can slow transit for some people.
- Caffeine reduction: Caffeine is a mild stimulant for bowel motility. If nausea has caused you to cut back on coffee, constipation may worsen as a side effect.
When Should You Call Your Prescriber?
Most constipation on semaglutide is uncomfortable but not dangerous. However, contact your care team if you notice any of the following:
- No bowel movement for five or more days despite home remedies
- Severe or worsening abdominal pain or cramping
- Nausea and vomiting alongside constipation (possible sign of serious gastric motility issues)
- Blood in the stool
- Symptoms that persist unchanged at the maintenance dose after several weeks
Persistent constipation that does not respond to dietary changes may also prompt a conversation about whether your current dose is right for you. Some prescribers extend time at a lower dose before escalating to allow GI symptoms to settle.
Frequently Asked Questions
Constipation is one of the more manageable side effects of semaglutide, but it is worth taking seriously from the start of treatment rather than waiting for it to become uncomfortable. If dietary changes and over-the-counter options are not providing enough relief, or if your symptoms are affecting your quality of life, speak with your prescriber — there are additional options available, and dose timing or escalation adjustments may help.
- Ozempic (semaglutide) FDA Prescribing Information, Novo Nordisk, 2023
- Wegovy (semaglutide) FDA Prescribing Information, Novo Nordisk, 2023
- Wilding JPH et al. 'Once-Weekly Semaglutide in Adults with Overweight or Obesity.' NEJM. 2021;384(11):989-1002.
- Marso SP et al. 'Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.' NEJM. 2016;375(19):1834-1844.
- Camilleri M. 'Glucagon-Like Peptide-1 Receptor Agonists and the Gastrointestinal Tract.' NEJM. 2021;384(20):1971-1972.
- National Institute of Diabetes and Digestive and Kidney Diseases. 'Constipation.' NIH, 2021.